Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study

Authors

Ezequiel Córdova (ORCID: https://orcid.org/0000-0002-9751-5208)
Essack Mitha
Veronica Bainbridge
S. Karthika (ORCID: https://orcid.org/0000-0002-2042-8333)
Antonella Castagna (ORCID: https://orcid.org/0000-0002-8338-9714)
Max Lataillade (ORCID: https://orcid.org/0000-0001-6103-8967)
Samit R. Joshi (ORCID: https://orcid.org/0000-0002-1332-5918)
Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
Alison Gaudion
J Oyee
Mar Masiá (ORCID: https://orcid.org/0000-0001-9878-2458)
Brian Wynne (ORCID: https://orcid.org/0000-0002-4043-2508)

Institutions

Vita-Salute San Raffaele University (IT)
Instituto de Salud Carlos III (ES)
GlaxoSmithKline (India) (IN)
ViiV Healthcare (United Kingdom) (GB)
Centro de Investigación Biomédica en Red (ES)
Hospital General Universitario de Elche (ES)
Fundación para la Investigación, Docencia y Prevención del Cáncer (AR)
Indian River State College (US)

Publication Details

Journal: EClinicalMedicine
Published: 2025-10-18
DOI: https://doi.org/10.1016/j.eclinm.2025.103566
Citations: 1
Primary Topic: HIV/AIDS drug development and treatment
Type: article
Field-Weighted Citation Impact: 1.40

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study

Ezequiel Córdova, Essack Mitha, Veronica Bainbridge, S. Karthika et al.

Oct 18, 2025

1 citations

EClinicalMedicine

HIV/AIDS drug development and treatment

1.40

article

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study

Ezequiel Córdova, Essack Mitha, Veronica Bainbridge, S. Karthika, Antonella Castagna, Max Lataillade, Samit R. Joshi, Moti N. Ramgopal, Alison Gaudion, J Oyee, Mar Masiá, Brian Wynne

October 18, 2025article en

1 citations

Abstract

No abstract available for this paper.

EClinicalMedicineVol. 89

Vita-Salute San Raffaele University (IT), Instituto de Salud Carlos III (ES), GlaxoSmithKline (India) (IN), ViiV Healthcare (United Kingdom) (GB), Centro de Investigación Biomédica en Red (ES), Hospital General Universitario de Elche (ES), Fundación para la Investigación, Docencia y Prevención del Cáncer (AR), Indian River State College (US)

Openalex Percentile: Top 15%

HIV/AIDS drug development and treatment

1.40

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.